Publications by authors named "M Wadleigh"
Despite the substantial expenditures on health care in the United States, persistent underperformance in health system metrics necessitates innovative approaches to address complex patient needs. The MedVantage Clinic in New Orleans, Louisiana, offers a regionally tailored, value-based primary care model targeting patients with high social and medical needs. This study provides an evaluation of the efficacy of the MedVantage Clinic in improving the cost of care and service utilization for this population.
View Article and Find Full Text PDFArticle Synopsis
- - Asparaginase-containing regimens for acute lymphoblastic leukemia (ALL) result in a significant prevalence of venous thromboembolism (VTE) among adolescents and young adults, with 1-year and 2-year cumulative incidences of 31.9% and 33.5%, respectively, particularly during the ASP-based consolidation phase.
- - The study revealed that overweight or obese patients had a higher risk of developing VTE (39.2%) compared to those with a normal BMI (29.0%), and overall survival rates were similar regardless of VTE occurrence, at around 91.5%.
- - Despite the frequent occurrence of VTE, especially types like pulmonary embolism and deep vein thrombosis,
Article Synopsis
- Dasatinib is a treatment for Philadelphia chromosome-positive (Ph+) acute leukemia, but some patients develop resistance, leading to the exploration of combining it with asciminib, an allosteric inhibitor to enhance efficacy.
- In a phase 1 study involving 24 adults, researchers aimed to determine the maximum tolerated dose of asciminib when used alongside dasatinib and prednisone for Ph+ acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in lymphoid blast crisis.
- Results showed that the combination led to high rates of complete hematologic and cytogenetic remission, with the recommended dose of asciminib being 80 mg daily, while also demonstrating safety and minimal severe side effects.
Mutations in the cohesin complex components (STAG2, RAD21, SMC1A, SMC3, and PDS5B) are recurrent genetic drivers in myelodysplastic neoplasm (MDS) and acute myeloid leukemia (AML). Whether the different cohesin subunit mutations share clinical characteristics and prognostic significance is not known. We analyzed 790 cohesin-mutant patients from the Dana-Farber Cancer Institute (DFCI) and the Munich Leukemia Laboratory (MLL), 390 of which had available outcome data, and identified subunit-specific clinical, prognostic, and genetic characteristics suggestive of distinct ontogenies.
View Article and Find Full Text PDFImportance: Patients often visit the emergency department (ED) near the end of life. Their common disposition is inpatient hospital admission, which can result in a delayed transition to hospice care and, ultimately, an inpatient hospital death that may be misaligned with their goals of care.
Objective: To assess the association of hospice use with a novel multidisciplinary hospice program to rapidly identify and enroll eligible patients presenting to the ED near end of life.